Question ID: WS-17
Submitted by: John Baron
January 27, 2011
Does DFMO really seriously impede colorectal carcinogenesis, as suggested in a recent clinical trial with an adenoma endpoint? Does this imply that polyamines are central to the development of neoplasia in the large bowel? Meysekens et al reported that DFMO + sulindac reduced the risk of all adenomas by about 70%, and reduced the risk of advanced adenomas by more than 90%. These findings are substantially more marked than those of any other chemopreventive agent. Since DFMO is a designer drug that inhibits ornithine decarboxylase, the first step in the synthesis of polyamines, these results imply that polyamines may be central to colorectal carcinogenesis.
This question has not yet been evaluated by users |
Comments